SIG Brokerage’s Novo Nordisk NVO Stock Holding History

SIG Brokerage’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,986	Closed	-$204K	–	822
2025 Q3	$221K	Sell	3,986 -13,052	-77%	-$764K	0.01%	663
2025 Q2	$1.18M	Buy	+17,038	New	+$1.16M	0.03%	318
2025 Q1	–	Sell	-49,626	Closed	-$4.1M	–	671
2024 Q4	$4.27M	Buy	+49,626	New	+$5.37M	0.23%	74

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

SIG Brokerage's NVO Position: Q4 2025 in Review

SIG Brokerage sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,986 shares — an estimated $204K sold.

SIG Brokerage first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $4.27M in Q4 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

SIG Brokerage reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
SIG Brokerage sold 3,986 Novo Nordisk shares in Q4 2025, an estimated $204K.
SIG Brokerage first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
SIG Brokerage's Novo Nordisk position peaked at $4.27M in Q4 2024.
1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on SIG Brokerage's 13F filing for Q4 2025, filed 17 Feb 2026.